The cardiac resynchronization therapy global market report 2024from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Cardiac Resynchronization Therapy Market, 2024report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The cardiac resynchronization therapy market size has grown strongly in recent years. It will grow from $5.89 billion in 2023 to $6.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to growth in the geriatric population, an increased incidence of heart failure, growth in investments in R&D for CRT device innovation, increased awareness about the therapy’s benefits, physician training programs, and competitive landscape dynamics.
The cardiac resynchronization therapy market size is expected to see strong growth in the next few years. It will grow to $8.22 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to the increasing prevalence of heart failure and cardiac disorders, growth in the geriatric population, a higher incidence of cardiovascular diseases, the need for CRT therapy, improvements in pacemakers and defibrillator treatment, and increasing awareness about CRT therapy. Major trends in the forecast period include the adoption of CRT-D devices over traditional pacemakers, the integration of advanced technology, expansion of CRT therapy, the integration of artificial intelligence, and the adoption of machine learning.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/cardiac-resynchronization-therapy-global-market-report
Scope Of Cardiac Resynchronization Therapy Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Cardiac Resynchronization Therapy Market Overview
Market Drivers –
The increase in the prevalence of cardiovascular diseases is expected to propel the growth of the cardiac resynchronization therapy market going forward. Cardiovascular diseases (CVD) refer to a category of illnesses that affect the heart and blood vessels. Cardiovascular disease is increasing owing to a variety of factors, including aging populations, unhealthy lifestyles, rising tobacco use, sedentary behavior, and inadequate diets. Cardiac resynchronization therapy (CRT) helps cardiovascular diseases, such as heart failure, by improving the coordination of the heart’s contractions through the delivery of synchronized electrical impulses. For instance, in May 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, the number of people who died from heart disease in the US increased from 690,882 in 2020 to 695,000 in 2021. Therefore, the increase in the prevalence of cardiovascular diseases is driving the growth of the cardiac resynchronization therapy market.
Market Trends –
Major companies operating in the cardiac resynchronization therapy market are focused on developing implantable devices to improve treatment outcomes for heart failure patients. Implantable devices in cardiac resynchronization therapy (CRT) coordinate the heart’s ventricles’ contractions, improving pumping efficiency and managing heart failure symptoms. For instance, in February 2024, MicroPort Scientific Corporation, a China-based medical device company, launched the GALI SonR cardiac resynchronization therapy and defibrillation device (CRT-D), an implantable device and the Navigo 4LV left ventricular pacing leads in Japan. This is the first and only CRT hemodynamic sensor designed to automatically optimize patients once a week and, more crucially, while the patient is active, allowing real-life optimization. The clinically established SonR algorithm has shown a 35% risk reduction in heart failure hospitalization, and it will also help to ensure the well-being and safety of the CRT-D patient.
The cardiac resynchronization therapy market covered in this report is segmented –
1) By Type: Cardiac Resynchronization Therapy (CRT)-Defibrillator, Cardiac Resynchronization Therapy (CRT)-Pacemaker
2) By Age: Below 44 Years, 45-64 Years, 65-84 Years, Above 85 Years
3) By End-Use: Hospitals, Cardiac Care Centers, Ambulatory Surgical Centers
Get an inside scoop of the cardiac resynchronization therapy market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=15531&type=smp
Regional Insights –
North America was the largest region in the cardiac resynchronization therapy market in 2023. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac resynchronization therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the cardiac resynchronization therapy market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Terumo Corporation, Biotronik SE & Co. KG, Lepu Medical Technology (Beijing) Co. Ltd., Integer Holdings Corporation, Merit Medical Systems Inc., LivaNova PLC, MicroPort Scientific Corporation, Sorin Group, Berlin Heart GmbH, EBR Systems Inc., Corvia Medical Inc., Recor Medical, Jarvik Heart Inc., Cardiac Dimensions Inc., Farapulse Inc., Osypka Medical GmbH, Japan Medical Device Corporation , Imricor Medical Systems Inc., Vascular Dynamics Inc., Svelte Medical Systems, Aleva Neurotherapeutics, BioSig Technologies Inc.
Table of Contents
1. Executive Summary
2. Cardiac Resynchronization Therapy Market Report Structure
3. Cardiac Resynchronization Therapy Market Trends And Strategies
4. Cardiac Resynchronization Therapy Market – Macro Economic Scenario
5. Global Cardiac Resynchronization Therapy Market Size and Growth
.
.
.
32. Global Cardiac Resynchronization Therapy Market Competitive Benchmarking
33. Global Cardiac Resynchronization Therapy Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Cardiac Resynchronization Therapy Market
35. Cardiac Resynchronization Therapy Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
